Jonathan W. Goldman

Associate Professor

UCLA

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jonathan W. Goldman is an Associate Professor at UCLA, United States. His research focuses on oncology, particularly the treatment of lung cancer and breast cancer, as evidenced by his recent articles investigating the efficacy of various inhibitors and therapies. His work encompasses areas such as small-molecule inhibitors, genomic landscapes of lung cancer, and the analysis of molecular residual disease in advanced malignancies.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (13)

Everett E. Vokes

University of Chicago

UNITED STATES

View details

Neil Wenger

Professor

UCLA Health

UNITED STATES

View details

Marina Garassino

Università degli Studi di Torino

ITALY

View details

Terufumi Kato

Chief Physician

Kanagawa Cancer Center

JAPAN

View details

Keunchil Park

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

Gerald Falchook

UNITED STATES

View details

Matthias Scheffler

University Hospital Bonn

GERMANY

View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Satish Nadig

Chief, Division of Transplant; Director, Comprehensive Transplant Center

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Ruli Gao

Assistant Professor

Northwestern University

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Katrina Pedersen

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan W. Goldman

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy

Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Collaborators (13)

Everett E. Vokes

Neil Wenger

Marina Garassino

Terufumi Kato

Keunchil Park

Bartosz Chmielowski

Gerald Falchook

Matthias Scheffler

David S. Hong

Satish Nadig

Ruli Gao

Timothy Yap

Katrina Pedersen

Make your next move.